EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment

Mikael Sunnåker iD, Christian Källgren, Joanna Parkinson, Corina Dota, Christer Gottfridsson, David Janzén, Anita Andersson, Glenn Carlson

Pharmacology Research & Perspectives · 2025-10 · 13 (5)

DOI: 10.1002/prp2.70181 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 13.10.2025. Verfasst von Mikael Sunnåker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Swed…. Hauptthemen laut MEDLINE: Long QT Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, CinCor Pharma, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baxdrostat is a novel, highly potent, selective, competitive inhibitor of human aldosterone synthase currently under development for the treatment of uncontrolled and resistant hypertension and chronic kidney disease. We assessed the risk of QTc‐interval prolongation with baxdrostat using concentration‐QTc (C‐QTc) modeling in healthy adult participants using data from two placebo‐controlled Phase 1 studies: a multiple‐ascending dose (MAD) study of baxdrostat 0.5–5 mg ( N = 56; NCT05500820) and a Phase 1 four‐way crossover thorough QT/QTc (TQT) study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of baxdrostat at supratherapeutic doses of 16 and 32 mg ( N = 28; NCT06194032). In the TQT study, 28 participants were randomized to one of four treatment sequences (each n = 7) of baxdrostat 16 mg, baxdrostat 32 mg, placebo and open‐label moxifloxacin 400 mg. Digital electrocardiogram and pharmacokinetic data were collected at baseline and up to 48 h post dose. Dependent and independent variables of the pre‐specified linear mixed‐effect model were placebo‐corrected baseline‐adjusted ΔΔQTcF and baxdrostat plasma concentrations, respectively. Results were consistent between the two C‐QTc modeling analyses. Baxdrostat treatment did not produce QT‐interval prolongation, both at concentrations of interest and geometric mean of the maximum observed plasma concentration. Upper bounds of the two‐sided 90% confidence interval for the ΔΔQTcF mean estimates were < 10 ms. Pharmacokinetic data for the 16 and 32 mg doses in the TQT study were as expected, and both doses were well tolerated. These data illustrate that baxdrostat is not associated with the risk of QT‐interval prolongation at therapeutic and supra‐therapeutic concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeHumansMaleAdultFemaleCross-Over StudiesElectrocardiographyMiddle AgedDose-Response Relationship, DrugDouble-Blind MethodYoung AdultCytochrome P-450 CYP11B2Models, BiologicalHealthy VolunteersMoxifloxacin

Stichwörter der Autor:innen

QT‐interval prolongationaldosterone inhibitorbaxdrostatconcentration‐QTc modelingdrug safetyhypertension

Substanzen

Cytochrome P-450 CYP11B2Moxifloxacin

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Cardiovascular Safety Centre of Excellence, Global Patient Safety, Oncology R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Late Development CVRM, AstraZeneca, Gaithersburg, Maryland, USA.

ORCID-Profile: Mikael Sunnåker

Förderung

  • AstraZeneca
  • CinCor Pharma, Inc.

Zitieren

APA

Sunnåker, M., Källgren, C., Parkinson, J., Dota, C., Gottfridsson, C., Janzén, D., Andersson, A., & Carlson, G. (2025). No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment. Pharmacology Research & Perspectives, 13(5). https://doi.org/10.1002/prp2.70181

Vancouver

Sunnåker M, Källgren C, Parkinson J, Dota C, Gottfridsson C, Janzén D, et al. No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment. Pharmacology Research & Perspectives. 2025;13(5). doi:10.1002/prp2.70181

BibTeX
@article{Sunnker2025,
  author = {Sunnåker, Mikael and Källgren, Christian and Parkinson, Joanna and Dota, Corina and Gottfridsson, Christer and Janzén, David and Andersson, Anita and Carlson, Glenn},
  title = {No Evidence of QTc Interval Prolongation With Baxdrostat Treatment: Concentration–QTc Modeling Assessment},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  volume = {13},
  number = {5},
  doi = {10.1002/prp2.70181}
}
Kostenlos starten →